Allergen Immunotherapy

A Breakthrough in Immunotherapy

For over a century, clinicians and scientists have failed at producing a safe and effective immunotherapy solution for poison ivy and poison oak.

BOME has made groundbreaking discoveries about how allergens need to be introduced to Antigen-Presenting Cells (APCs) and the human immune system.

Our patented allergen immunotherapy delivers up to 90-100% efficacy in treating allergic contact dermatitis caused by poison ivy and poison oak, with no significant adverse effects.

The Problem

Allergen Immunotherapy has been used as a treatment since 19111. Subcutaneous (under the skin) “Allergy Shots” as an immunotherapy for Poison Ivy / Oak and other poisonous plants does not work. Therapy has advanced; however, some allergens remain untreatable.
  • 85% of the population are prone to developing allergies to poisonous plants 2
  • Severe allergic reactions to Poison Ivy and Poison Oak (PI/PO) continue to impact ~29M people 2
  • There are NO current immunotherapy solutions for Poison Ivy and Poison Oak 3

Introducing Antigen Delivery by Precipitation

BOME has developed a proprietary process called Antigen Delivery by Precipitation (ADBP). ADBP is a highly effective process for introducing antigens to the human immune system, which can result in a dramatic increase to allergen tolerance and a reduction in sensitivity severity.

Although our current focus is to develop an immunotherapy for poisonous plants, we believe there is great potential for additional future immunotherapy applications and vaccines using ADBP as a framework for developing and strengthening the human immune system.